Boston Scientific (BSX) Cash from Operations (2009 - 2026)

Boston Scientific has disclosed Cash from Operations across 18 years of filings, most recently posting $1.5 billion for Q2 2026.

• In Q2 2026, Cash from Operations rose 14.62% year-over-year to $1.5 billion; the TTM figure through Jun 2026 stood at $4.5 billion (up 5.69% YoY), while the FY2025 annual figure was $4.5 billion, up 31.99% from the prior year.
• Cash from Operations came in at $1.5 billion for Q2 2026 at Boston Scientific, up from $348.0 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $1.5 billion in Q2 2026 to a low of -$58.0 million in Q1 2022.
• Average Cash from Operations over 5 years is $767.8 million, with a median of $752.5 million recorded in 2022.
• Year-over-year, Cash from Operations sank 120.42% in 2022 and surged 427.59% in 2023.
• Over 5 years, Cash from Operations stood at $807.0 million in 2022, then advanced by 18.59% to $957.0 million in 2023, then jumped by 52.14% to $1.5 billion in 2024, then fell by 6.32% to $1.4 billion in 2025, then increased by 8.06% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were $1.5 billion in Q2 2026, $348.0 million in Q1 2026, and $1.4 billion in Q4 2025.